To help countries achieve equitable access to quality, effective, affordable and safe Hepatitis C treatments, WHO this week published an analysis of the patent situation for seven new hepatitis treatments.
WHO has called on manufacturers of in vitro Ebola diagnostics to submit their products for emergency review to fast-track reliable diagnosis of the virus currently ravaging four West African countries. Assessment of the diagnostics will determine if they are fit for use and list the acceptable products on the WHO web site. This will allow the manufacturers to offer their products to international agencies or countries involved in the battle against the current and worst Ebola outbreak since 1976, when the virus was discovered.
New study shows better use of medicines in countries adopting WHO ‘essential medicines’ policies
The wrong use of medicines is a threat to patients’ health and a global public health problem. The consequences of over- or under-using medicines can result in serious negative drug reactions, sometimes leading to death, drug resistance and a waste of financial resources. The World Health Organization (WHO) has advocated the essential medicines model since 1978 and has developed a range of policies to promote good use of medicines. A study published in PLoS reveals that policies recommended by WHO promote better use of medicines and therefore better patient outcomes and significant cost savings in a number of low-income countries.
After 2 days of discussion on potential Ebola therapies and vaccines, more than 150 participants, representing the fields of research and clinical investigation, ethics, legal, regulatory, financing, and data collection, identified several therapeutic and vaccine interventions that should be the focus of priority clinical evaluation at this time.